| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 37.78 |
| ObsEva SA | 22.94 |
| Sofinnova Investments, Inc. | 4.37 |
| NEA Management Co. LLC | 4.22 |
| Armistice Capital LLC | 3.99 |
| Armistice Capital LLC | 2.66 |
| Medicxi Ventures (Jersey) Ltd. | 1.45 |
| Rock Springs Capital Management LP | 1.32 |
| Fidelity Management & Research Co. LLC | 1.25 |
| OrbiMed Advisors LLC | 1.20 |
| Logos Global Management LP | 1.07 |
| HBM Healthcare Investments | 0.99 |
| Omega Fund Management LLC | 0.92 |
| Omega Fund Management LLC | 0.92 |
| New Leaf Venture Partners LLC | 0.83 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 39 | 45 | 53 | 45 | 51 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Bilanz (in Mio. EUR) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 113 | 145 | 75 | 37 | 64 |
| Summe Anlagevermögen | 123 | 147 | 76 | 35 | 59 |
| Summe Aktiva | 135 | 167 | 104 | 65 | 89 |
Bilanz (in Mio. EUR) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 0 | 0 | 27 | 27 | 27 |
| Summe Fremdkapital | 13 | 21 | 55 | 57 | 57 |
| Summe Eigenkapital | 123 | 147 | 49 | 8 | 32 |
| Summe Passiva | 135 | 167 | 104 | 65 | 89 |
Adresse
| Chemin des Aulx, 12, 1228 Geneva | |
| Telefon | +41 (22) 552-38-40 |
| URL | http://www.obseva.com |
Management
|
Anne M. VanLent
Director |
|
Annette V. Clancy
Chairman |
|
Brandi Howard
Chief Clinical Officer |
|
Brian O'Callaghan
Chief Executive Officer & Director |
|
Catarina Edfjäll
Independent Director |
|
Clive Bertram
Chief Commercial Officer |
|
Edward Mathers
Independent Director |
|
Elke Bestel
VP, Head-Drug Safety & Pharmacovigilance |
|
Ernest Loumaye
Director |
|
Fabien de Ladonchamps
Chief Administrative Officer |
|
Jean-Pierre Gotteland
Chief Scientific Officer, Head-R&D |
|
Katja Buhrer
Chief Strategy Officer |
|
Luigi Marro
Chief Transformation Officer |
|
Stephanie Brown
Director |
|
William M. Brown
Chief Financial Officer |